

November 2, 2020

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
--	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Consolidation of shareholding in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey (Provet) to make Provet a Wholly Owned Subsidiary of the Company

Further to our announcement dated September 22, 2020 on proposed acquisition of 40% stake from Dr. Huseyin Aydin in Provet through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company, we would like to inform you that the said transaction has been completed.

On completion of the said transaction, Provet has become a Wholly Owned Subsidiary of the Company. The Consolidated Financials of Provet for the financial year 2019-20 are as mentioned below:

Particulars	Amount (₹ in millions)
Sales	1351
EBIDTA	408
Net Profit	209

We request you to take the above on your record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah

Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>